Navigation Links
GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
Date:11/6/2009

ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

Robert McNally, Ph.D., President and Chief Executive Officer commented, "We are pleased with our progress during the third quarter of 2009 on several fronts. Enrollment for our Phase 2a preventative trial being conducted by the HVTN is proceeding according to plan. We are looking forward to a pre-IND meeting with the FDA later this year to discuss our plans for a Phase 1 therapeutic trial in early 2010. With a modest cash burn rate, continuing support from the HVTN, our IPCAVD grant from the NIH and with our common stock purchase agreement with Fusion Capital in place, our finances are in order to take us into 2011. As we move forward, we believe we will be in a strong position to seek additional government and private support for advancing both our preventative and therapeutic vaccines through Phase 2b and Phase 3 clinical trials."

"These are exciting times for GeoVax and everyone involved in HIV/AIDS vaccine development," Dr. McNally continued. "The recently announced success of a Thailand-based Phase 3 trial for an HIV/AIDS vaccine candidate owned by Sanofi-Aventis and Global Solutions for Infectious Diseases is encouraging to us all and has brought renewed interest to the field. At GeoVax, we have always been confident in our ability to develop an effective vaccine and this recent news has shown that a vaccine is indeed possible."

Review of Financial Results

The Company recorded a net loss of $230,815 for the three months ended September 30, 2009, compared to $722,108 for the same period in 2008. For the nine months ended Septem
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
2. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
3. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
4. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
5. GeoVax Reports Progress on Its AIDS Vaccine Technology
6. GeoVax Secures $10 Million Financing Commitment
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
11. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Low ... FDA committee meeting in Hyattsville, Maryland ... meeting to assess the proper patient population for ... potential cardiovascular risk associated with TRT. Examining recent claims ... committee found that "available epidemiological studies do not ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... Africa, Dec. 23, 2011 Leatt Corporation (OTC: ... a neck brace system designed to help prevent potentially devastating ... announced that it held and webcast its 2011 Annual Meeting ... was present in person or by proxy. With ...
... 23, 2011 - Stupendous success on becoming Leader ... - Company,s main focus on ,Innovation & Creativity, ... Christmas present for Mr. Veeral Desai, Managing Director, Span Diagnostics ... nation,s most coveted ,ET NOW-IndiaMART Leaders of Tomorrow Awards 2011, ...
Cached Medicine Technology:Leatt Holds 2011 Annual Meeting of Shareholders 2Span Diagnostics Ltd. Hits Bull's eye at 'ET NOW-IndiaMART Leaders of Tomorrow Awards 2011' 2Span Diagnostics Ltd. Hits Bull's eye at 'ET NOW-IndiaMART Leaders of Tomorrow Awards 2011' 3
(Date:9/21/2014)... 21, 2014 “Cluster headaches are sometimes ... and difficult to resolve,” said Steve Young of Ew ... of a pain that is more intense.” , “It ... cluster headaches, or migraines, that medical research is pointing ... system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ...
(Date:9/21/2014)... California (PRWEB) September 21, 2014 According to ... experienced the highest birth rate since 1966 (10.5 births per ... in their early 40s has risen steadily by 2 percent ... includes births to women aged 50 and over) also rose, ... that there were more than nine times as many first ...
(Date:9/20/2014)... 2014 Weight Destroyer , a ... expert Michael Wren that has already helped tens of ... health conditions like high blood pressure, high cholesterol, and ... prompting an investigative review. , “Weight Destroyer is ... down by showing people what is truly effective when ...
(Date:9/20/2014)... (PRWEB) September 21, 2014 Increases ... contributing to greater waste treatment volumes. However, government ... diverting waste from landfill. According to IBISWorld industry ... have implemented strategies aimed at reducing the volume ... waste recycled and recovered.” Still, a large proportion ...
(Date:9/20/2014)... The print component of “Work-Life ... the Calgary Herald, with a circulation of approximately ... The digital component is distributed nationally through a ... of top news sites and partner outlets. To ... http://www.worklifebalanceinfo.ca . , The publication features an ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2
... United American,Healthcare Corporation has nominated Bruce R. Galloway for ... Meeting of Shareholders scheduled,for Friday, November 7, 2008., ... shares of United,American Healthcare,s common stock, Lloyd I. Miller ... The proposal for the election of directors,is more fully ...
... 4 The National Patient Safety Foundation,(NPSF) today ... forum for leading health care solutions providers to ... and,patients and their families -- all with the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ), "We are excited ...
... the University of Pennsylvania School of Medicine can now ... mature B-cells in the blood stream at any one ... germs to fight infections. , "There is a steady ... for humans," says senior author Michael P. Cancro, PhD, ...
... arthritis now have many more treatment options than in ... drugs, derived by modifying substances found in humans or ... treating the symptoms. The cost of biologic DMARDs is ... cost 100 times more than a year,s supply of ...
... Pycnodysostosis, a condition from which the painter Henri de ... stature. This rare disease, surprisingly, provides a window into ... by deficiency of an enzyme known as cathepsin K ... in bone modeling and repair), leading to poor bone ...
... HOUSTON, Nov. 4 US Oncology today announced ... has,exceeded the $10 million mark in assisting more than ... Advantage in August 2006., "It was important when ... access to oral chemotherapies by easing the financial,burdens these ...
Cached Medicine News:Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Penn scientists show how body determines optimal amount of germ-fighting B cells 2Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3
... of emission at two different wavelengths (1064 and ... 1064 DW is able to select the delivered ... (with powers selectable among 4 and 100 W) ... 25 W). This second wavelength is very useful ...
Smartepil II is a laser particularly indicated for hair-removal where it has proved to be a valid instrument, even in the treatment of darker phototypes and telangiectasias of the face and legs....
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... SmartOffice Plus is a CO2 ... to 25 W. Its functions in ... for surgery requiring extreme laser intervention ... in medical studios, it comes with ...
Medicine Products: